<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32703060</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of poliovirus antibodies before and after polio vaccine switch in 2012 and 2017 in Beijing.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>396</EndPage><MedlinePgn>389-396</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2020.1778409</ELocationID><Abstract><AbstractText>In 2000, China was declared polio-free. However, in 2018, wild poliovirus (WPV) was still endemic in two of its neighboring countries, making WPV importation and outbreak alarming possibilities. This study documents the seroprevalence of poliovirus antibodies before and after the polio vaccine switch in 2012 and 2017 in Beijing. Cross-sectional population-based serologic surveys were conducted in 2012 and 2017 in Beijing. The study subjects were selected from 10 different age groups (&lt;1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, and &#x2265;40&#xa0;y) using a multi-stage-stratified sampling method. Neutralizing antibody titers against poliovirus serotypes 1 (P1), 2 (P2), and 3 (P3) were assayed by World Health Organization standards. The seropositive rates (SR) and geometric mean titer (GMT) of the neutralizing antibodies were 91.71% and 1:130.26, respectively, for P1, 94.09% and 1:113.39, respectively, for P2, and 88.78% and 1:79.65, respectively, for P3 before the switch in 2012, and 87.78% and 1:108.93, respectively, for P1, and 81.67% and 1:70.56, respectively, for P3 after the switch in 2017, with a statistically significant difference for P1 and P3 between 2012 and 2017. The neutralizing antibodies for all poliovirus serotypes differed among different age and vaccination groups in both 2012 and 2017. After switching polio vaccines twice in 2014 and 2016, the P1 and P3 polio antibody levels were lower in 2017 than in 2012. The P2 antibody levels were determined from the first dose of IPV. The seroprevalence of poliovirus antibodies after adjustment of the immunization schedule of the polio vaccine on January 1, 2020, must be further monitored.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Center for Disease Control and Prevention , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhujiazi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Herun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Maozhong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunization and Prevention, Beijing Research Centre for Preventive Medicine , Beijing, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068476" MajorTopicYN="N" Type="Geographic">Beijing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="Y">Poliovirus Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>No potential conflict of interest was disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32703060</ArticleId><ArticleId IdType="pmc">PMC7899662</ArticleId><ArticleId IdType="doi">10.1080/21645515.2020.1778409</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . 10 facts about the eradication of poliomyelitis [EB/OL]. 2017. 
April
25. https://www.who.int/features/factfiles/polio/en/</Citation></Reference><Reference><Citation>Global Wild Poliovirus 2014-2019 . 2019. Accessed 9November 2019
http://polioeradication.org/wp-content/uploads/2016/08/weekly-polio-global-update-03Aug19.pdf</Citation></Reference><Reference><Citation>Moturi EK, Porter KA, Wassilak SG, Tangermann RH, Diop OM, Burns CC, Jafari H.. EIS officer, CDC. Progress toward polio eradication - worldwide, 2013-2014. MMWR Morb Mortal Wkly Rep. 2014;63:468&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779464</ArticleId><ArticleId IdType="pubmed">24871252</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo HM, Yu WZ, Wen N, Wang HB, Dong CX, Fan CX, Li L. Application of poliomyelitis vaccine and recommendation on switch of immunization strategies in China. Chin J Vaccines Immunization. 2014;20:172&#x2013;76.</Citation></Reference><Reference><Citation>Zhang LF, Wen N, Cao LS, Su QR, Fan CQ, Yu WZ, Zheng JS, Li L, Wang HQ, HM L. Comparison of poliomyelitis vaccine routine immunization data from different sources in 8 provinces (municipalities) in China. Chin J Vaccines Immunization. 2015;21:400&#x2013;04.</Citation></Reference><Reference><Citation>Yu WZ, Wen N, Zhang Y, Wang HB, Fan CX, Zhu SL, Xu WB, Liang XF, Luo HM, Li L. Poliomyelitis eradication in china: 1953&#x2013;2012. J Infect Dis. 2014;210(Suppl 1):S268&#x2013;74. doi:10.1093/infdis/jit332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit332</ArticleId><ArticleId IdType="pubmed">25316845</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HB, Zhu SL, Zheng JS. Sero-survey of polio antibodies during wild poliovirus outbreak in Southern Xinjiang Uygur Autonomous Region, China. PLoS One. 2014;9:e800691&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081020</ArticleId><ArticleId IdType="pubmed">24991811</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo HM, Zhang Y, Wang XQ, Yu WZ, Wen N, Yan DM, Wang HQ, Wushouer F, Wang HB, Xu AQ, et al. Identification and control of a poliomyelitis outbreak in Xinjiang, China. N Engl J Med. 2013;369(21):1981&#x2013;90. doi:10.1056/NEJMoa1303368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303368</ArticleId><ArticleId IdType="pubmed">24256377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Ma R, Zhou T, Yang F, Wu J, Sun H, Liu F, Lu L, Li X, Zuo S, et al. Introduction of inactivated poliovirus vaccine and impact on vaccine-associated paralytic poliomyelitis-Beijing, China, 2014&#x2013;2016. MMWR Morb Mortal Wkly Rep. 2017;66(49):1357&#x2013;61. doi:10.15585/mmwr.mm6649a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6649a4</ArticleId><ArticleId IdType="pmc">PMC5730215</ArticleId><ArticleId IdType="pubmed">29240729</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Progress toward poliomyelitis eradication&#x2014;Myanmar,1996&#x2013;1999. MMWR Morb Mortal Wkly Rep. 1999;48(42):967&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">10553811</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Importation of wild poliovirus into Qinghai Province&#x2014;China, 1999. MMWR Morb Mortal Wkly Rep. 2000;49(6):113&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11243437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen N, Luo HM, Wang HB, Cui FQ, Zheng H, Wang FZ, Zhang Y, Fan CX, Hao LX, Ma C, et al. Study on risk assessment and response of wild poliovirus importation after polio imported into Xinjiang Uygur Autonomous Region, 2011. Chin J Vaccines Immunization. 2013;19:193&#x2013;98.</Citation></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587&#x2013;635. doi:10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362(25):2360&#x2013;69. doi:10.1056/NEJMoa0910074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0910074</ArticleId><ArticleId IdType="pubmed">20573924</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Progress toward the global interruption of wild poliovirus type 2 transmission, 1999. MMWR Morb Mortal Wkly Rep. 1999;48(33):736&#x2013;738, 747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10503575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HB, Luo HM, Li L, Fan CX, Hao LX, Ma C, Su QR, Yang H, Reilly KH, Wang HQ, et al. Vaccine-derived poliovirus surveillance in China during 2001-2013: the potential challenge for maintaining polio free status. BMC Infect Dis. 2017;17(1):742&#x2013;49. doi:10.1186/s12879-017-2849-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2849-z</ArticleId><ArticleId IdType="pmc">PMC5712118</ArticleId><ArticleId IdType="pubmed">29197328</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake IM, Pons-Salort M, Molodecky NA, Diop OM, Chenoweth P, Bandyopadhyay AS, Zaffran M, Sutter RW, Grassly NC. Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine. N Engl J Med. 2018;379(9):834&#x2013;45. doi:10.1056/NEJMoa1716677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716677</ArticleId><ArticleId IdType="pmc">PMC5985919</ArticleId><ArticleId IdType="pubmed">30157398</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipursky S, Vandelaer J, Polio Endgame: BA. Lessons learned from the immunization systems management group. J Infect Dis. 2017;216(suppl_1):S9&#x2013;S14. doi:10.1093/infdis/jiw592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw592</ArticleId><ArticleId IdType="pmc">PMC5853539</ArticleId><ArticleId IdType="pubmed">28838174</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Manual for the virological investigation of polio[EB/OL]. WHO/EPI/GEN 1997.</Citation></Reference><Reference><Citation>Zarocostas J. Imports of polio to China and western Africa threaten global eradication. BMJ. 2011;343(343):d6186. doi:10.1136/bmj.d6186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d6186</ArticleId><ArticleId IdType="pubmed">21952462</ArticleId></ArticleIdList></Reference><Reference><Citation>Opare JKL, Odoom JK, Akweongo P, Afari EA1, Pappoe M. Poliovirus antibody levels and lameness among individuals in three regions of Ghana. Hum Vaccin Immun. 2019; 15(9):2050-2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773404</ArticleId><ArticleId IdType="pubmed">31265356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HB, Yu WZ, Wang XQ, Wushouer F, Wang J-P, Wang D-Y, Cui F-Q, Zheng J-S, Wen N, Ji Y-X. An outbreak following importation of wild poliovirus in Xinjiang Uyghur Autonomous Region, China, 2011. BMC Infect Dis. 2015;15(1):34&#x2013;42. doi:10.1186/s12879-015-0761-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-0761-y</ArticleId><ArticleId IdType="pmc">PMC4336520</ArticleId><ArticleId IdType="pubmed">25636581</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MK, Konde MK, Didi-Ngossaki BH, Ndinga E, Yogolelo R, Salla M, Shaba K, Everts J, Armstrong GL, Daniels D, et al. An outbreak of wild poliovirus in the Republic of Congo, 2010-2011. Clin Infectious Dis. 2012;55(10):1291&#x2013;98. doi:10.1093/cid/cis714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis714</ArticleId><ArticleId IdType="pmc">PMC4663667</ArticleId><ArticleId IdType="pubmed">22911642</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Polio field census and vaccination of underserved populations - Northern Nigeria, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013;62(33):663&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604797</ArticleId><ArticleId IdType="pubmed">23965829</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Orenstein W. A world free of polio&#x2013;the final steps. N Engl J Med. 2016;374(6):501&#x2013;03. doi:10.1056/NEJMp1514467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1514467</ArticleId><ArticleId IdType="pubmed">26863350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Hwang S, Lee S, Kwon Y, Park K, Park YJ, Bae GR, Lee SW, Jeong YS, Hyeon JY. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people. BMC Infect Dis. 2015;15(1):164. doi:10.1186/s12879-015-0894-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-0894-z</ArticleId><ArticleId IdType="pmc">PMC4391131</ArticleId><ArticleId IdType="pubmed">25881203</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Polio vaccines: WHO position paper.[EB/OL]. 2016. 
https://www.who.int/immunization/documents/positionpapers/en/</Citation><ArticleIdList><ArticleId IdType="pubmed">27894720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Li X, Zhang H, Liu D, Zhang Z, Wang H, Liu F, Ning Z, Li J, Pang X. Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants. Vaccine. 2015;33(36):4653&#x2013;58. doi:10.1016/j.vaccine.2014.08.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.091</ArticleId><ArticleId IdType="pubmed">25681659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC, Andino R. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599. doi:10.1371/journal.ppat.1002599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002599</ArticleId><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Simasathien S, Migasena S, Beuvery C, van Steenis G, Samakoses R, Pitisuttitham P, Vesikari T. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) Versus standard oral poliovirus vaccine (OPV) in Thai infants. Scand J Infect Dis. 1994;26(6):731&#x2013;38. doi:10.3109/00365549409008643.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365549409008643</ArticleId><ArticleId IdType="pubmed">7747098</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating Vaccine-derived Poliovirus(cVDPV) . [EB/OL]. 2019. http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>